```html

Xanthoma Planum: A Complete Medical Guide

Overview

Xanthoma planum (also called plane xanthoma, flat xanthoma, or simply “xanthoma”) is a skin disorder characterized by flat or slightly raised, yellow‑to‑orange patches that typically appear on the forehead, eyelids, neck, and other areas of the trunk. The lesions are collections of lipid‑laden macrophages (foam cells) within the dermis, giving the skin its distinctive hue.

The condition is most often a cutaneous manifestation of an underlying lipid metabolism disorder, particularly familial hypercholesterolemia (FH) or other primary dyslipidemias. However, it can also arise secondary to liver disease, cholestasis, or certain medications.

• Who it affects: It can occur at any age, but the majority of cases are seen in adolescents and young adults with genetically‑driven hyperlipidemia. Rarely, it appears in older adults as a sign of secondary lipid disturbance.
• Prevalence: Precise worldwide prevalence is difficult to determine because many cases go undiagnosed. In patients with heterozygous FH, plane xanthomas are reported in 10‑15 % of individuals, while in homozygous FH the prevalence rises to 70‑80 % (Mayo Clinic, 2023).

Symptoms

Symptoms are mainly visual, but some patients experience discomfort.

• Flat, yellow‑orange patches – Most common finding; lesions are typically 0.5–3 cm in diameter, smooth, and non‑palpable.
• Location – Forehead and eyelids (often called “xanthelasma” when limited to the eyelids), neck, upper chest, back, and sometimes the palms or soles.
• Texture – Skin feels normal; lesions are not raised like nodular xanthomas.
• Itching or mild irritation – Uncommon but can occur if lesions become inflamed.
• Associated systemic signs – May coexist with tendon xanthomas, eruptive xanthomas, or lipid‑related cardiovascular symptoms such as chest pain, claudication, or early‑onset heart disease.

Causes and Risk Factors

Primary (Genetic) Causes

• Familial hypercholesterolemia (FH) – Mutations in the LDLR, APOB, or PCSK9 genes reduce LDL‑receptor function, leading to chronically elevated LDL‑cholesterol.
• Familial combined hyperlipidemia – Overproduction of VLDL and LDL particles.
• Familial dysbetalipoproteinemia (type III hyperlipoproteinemia) – Defective ApoE2/E2 genotype causing accumulation of remnant lipoproteins.

Secondary (Acquired) Causes

• Cholestatic liver disease (e.g., primary biliary cholangitis, primary sclerosing cholangitis)
• Nephrotic syndrome
• Hypothyroidism
• Use of certain drugs (e.g., isotretinoin, protease inhibitors, high‑dose estrogen therapy)

Risk Factors

• Family history of premature coronary artery disease or known lipid disorder.
• Elevated LDL‑C >190 mg/dL (≥4.9 mmol/L) in adults.
• Smoking, hypertension, and diabetes, which accelerate atherosclerosis and may exacerbate skin lesions.
• Obesity and sedentary lifestyle – contribute to secondary dyslipidemia.

Diagnosis

Diagnosis is a two‑step process: clinical recognition of the skin lesions and laboratory assessment for underlying lipid abnormalities.

Clinical Evaluation

• Visual inspection by a dermatologist or primary‑care clinician.
• Dermatoscopy can help differentiate xanthoma planum from other pigmented lesions (e.g., lentigines, melasma).
• Skin biopsy (rarely needed) – Histology shows foamy macrophages in the superficial dermis, confirming the diagnosis.

Laboratory Tests

Test	Purpose
Lipid panel (total cholesterol, LDL‑C, HDL‑C, triglycerides)	Identify primary dyslipidemia.
Liver function tests (ALT, AST, ALP, bilirubin)	Screen for cholestatic disease.
Thyroid‑stimulating hormone (TSH)	Detect hypothyroidism.
Renal function (creatinine, urine protein)	Rule out nephrotic syndrome.
Genetic testing (LDLR, APOB, PCSK9, APOE)	Confirm inherited lipid disorders when FH is suspected.

Imaging (if indicated)

• Carotid intima‑media thickness ultrasound or coronary CT angiography to assess atherosclerotic burden in high‑risk patients.

Treatment Options

Therapy focuses on two goals: (1) normalizing lipid levels to prevent cardiovascular disease, and (2) reducing or removing the cutaneous lesions.

Medication

• Statins – First‑line agents (e.g., atorvastatin, rosuvastatin) lower LDL‑C by 30‑50 % and can cause regression of xanthomas over months to years (NIH, 2022).
• Ezetimibe – Adds ~15‑20 % LDL‑C reduction when combined with a statin.
• PCSK9 inhibitors (alirocumab, evolocumab) – Useful for homozygous FH or statin‑intolerant patients; can lower LDL‑C >60 % and lead to rapid lesion shrinkage.
• Bile‑acid sequestrants (cholestyramine) – Adjunctive therapy, especially in patients with cholestasis.
• Fibrates – Primarily lower triglycerides; may help in mixed dyslipidemia.
• Niacin – Less commonly used due to side‑effects, but can raise HDL‑C.

Procedural / Cosmetic Options

• Laser therapy – Q‑switched or pulsed‑dye lasers can reduce pigment and improve texture; multiple sessions may be required.
• Cryotherapy – Freezing lesions; effective for isolated small patches.
• Surgical excision – Reserved for thickened or refractory lesions; risk of scarring.
• Chemical peels (trichloroacetic acid) – Can lighten superficial plaques but must be performed by a dermatologist.

Lifestyle Modifications

• Adopt a heart‑healthy diet (Mediterranean‑style, ≤30 % of calories from fat, saturated fat <7 %).
• Increase soluble fiber (oats, beans, fruits) – helps lower LDL‑C.
• Engage in at least 150 minutes/week of moderate aerobic activity.
• Maintain a healthy weight (BMI 18.5–24.9 kg/m²).
• Quit smoking and limit alcohol intake.

Living with Xanthoma Planum

Daily Management Tips

• Medication adherence – Use a pill organizer or reminder app; never skip doses.
• Skin care – Gentle, fragrance‑free cleansers; avoid harsh scrubs that could irritate lesions.
• Sun protection – Broad‑spectrum SPF 30+ sunscreen reduces discoloration and protects against UV‑induced skin damage.
• Regular monitoring – Check lipid panel every 3–6 months until stable, then at least annually.
• Support networks – Connect with FH advocacy groups (e.g., FH Foundation) for education and emotional support.

Psychosocial Considerations

Visible skin lesions can affect self‑esteem. Counseling, cosmetic treatment options, or support groups can mitigate anxiety or depression associated with appearance concerns.

Prevention

Because xanthoma planum is usually a marker of underlying lipid disorder, primary prevention targets the metabolic cause.

• Screen family members early: lipid testing in first‑degree relatives as soon as age 2 years for homozygous FH or age 10 years for heterozygous FH (CDC, 2024).
• Maintain a lipid‑friendly diet from childhood; encourage physical activity in schools.
• Control secondary contributors—manage hypothyroidism, treat chronic liver disease, and address nephrotic syndrome promptly.
• Avoid medications known to raise lipids unless medically necessary.

Complications

If left untreated, Xanthoma planum itself is benign, but the associated dyslipidemia dramatically raises the risk of serious health problems.

• Atherosclerotic cardiovascular disease (ASCVD) – Premature coronary artery disease, myocardial infarction, stroke.
• Tendon xanthomas – Can impair joint function, especially when involving Achilles or extensor tendons.
• Pancreatitis – Particularly in severe hypertriglyceridemia.
• Liver disease progression – In cholestatic states, worsening jaundice and fibrosis.
• Psychological impact – Chronic skin lesions may lead to depression or social withdrawal.

When to Seek Emergency Care

References

• Mayo Clinic. “Familial hypercholesterolemia.” Updated 2023.
• National Institutes of Health (NIH). “Statin therapy and skin xanthoma regression.” 2022.
• Cleveland Clinic. “Xanthomas: Types, causes, and treatment.” 2024.
• Centers for Disease Control and Prevention (CDC). “Familial hypercholesterolemia screening guidelines.” 2024.
• World Health Organization (WHO). “Cardiovascular disease risk in lipid disorders.” 2023.
• American Heart Association. “2023 Guideline for the Management of Blood Cholesterol.”

```